There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on uniQure NV (QURE – Research Report), Protagonist Therapeutics (PTGX – Research Report) and ObsEva SA (OBSV – Research Report) with bullish sentiments.
uniQure NV (QURE)
H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on uniQure NV today and set a price target of $73. The company’s shares closed on Friday at $75.77, close to its 52-week high of $82.49.
“While the stock is trading ahead of our $73 target driven by fervent M&A speculation, we await preliminary data from AMT-130, uniQures’ Huntington disease gene silencing program, and potential IND clearance for AMT-180 as levers which could trigger a target revision. For a deep dive into disease modifying therapies in development for Huntington disease refer to Key Take-Aways from HD KOL Dinner .Our $73 target is based on a 12-year DCF analysis that incorporates rNPV of two clinical-stage pipeline products AMT-061 and AMT-130.”
According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 1.0% and a 44.1% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Voyager Therapeutics Inc, and Mersana Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for uniQure NV with a $95 average price target, which is a 25.4% upside from current levels. In a report released today, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $94 price target.
Protagonist Therapeutics (PTGX)
Protagonist Therapeutics received a Buy rating and a $23 price target from H.C. Wainwright analyst Douglas Tsao today. The company’s shares closed on Friday at $12.84.
“Valuation Our $23 price target for Protagonist is based on our sum-of-the-parts NPV valuation based on the company’s three primary development programs, PTG-300, PTG-200, and PN-943. Our DCF model utilizes a terminal decline rate of 10%, WACC-based discount rate of 11.7%.”
According to TipRanks.com, Tsao is a 3-star analyst with an average return of 2.1% and a 52.3% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals Inc, Minerva Neurosciences, and Revance Therapeutics.
Currently, the analyst consensus on Protagonist Therapeutics is a Moderate Buy with an average price target of $20.
ObsEva SA (OBSV)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on ObsEva SA, with a price target of $44. The company’s shares closed on Friday at $11.20, close to its 52-week low of $9.73.
“We remind investors that PRIMROSE 2 completed enrollment in December 2018. In anticipation of key progress in 2019 with linzagolix, nolasiban and OBE022, we reiterate our Buy rating and 12-month target of $44 per share.”
According to TipRanks.com, Selvaraju is a 4-star analyst with an average return of 4.2% and a 33.3% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ObsEva SA with a $41 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.